Alkyl Amines Chemicals Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q2 FY26 earnings call analysis: revenue, margin, capex, fundraise and order book outlook from management commentary.

Published 19 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹9.9K Cr

Volume growth in H1 FY'26 was marginally up but below the usual 10-15% annual growth expectation due to subdued demand. The first half of FY'26 has been subdued with marginal volume growth and flat topline due to demand pressures and geopolitical factors. - Volume growth expected to be lower than the usual 10-15% for FY'26. - Margins have been protected despite pricing pressures. - Demand is currently subdued across agrochemicals, pharma, and other industries but may improve if global trade volatility settles. - Capacity expansions, such as the new plant with a CAPEX of ~Rs.

From Alkyl Amines Chemicals Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹2,053

Market Cap

₹9.9K Cr

P/E Ratio

44.1

How does Alkyl Amines Chemicals Ltd rank in Chemicals & Petrochemicals?

Compare Alkyl Amines Chemicals Ltd against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

Alkyl Amines Chemicals Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹387 Cr, net profit ₹45 Cr.

Full financials →

📊 Revenue & Sales Performance

→Volume growth in H1 FY'26 was marginally up but below the usual 10-15% annual growth expectation due to subdued demand.
→Full year FY'26 volume growth is expected to remain subdued owing to global geopolitical and trade challenges.
→Demand in methylamines impacted more than ethylamines, with ethylamines focused more on the domestic market.
→Capacity utilization and demand growth for products like acetonitrile depend on market conditions; capacity expansion decisions will be made once utilization nears limits.
→New product launches are expected by early 2026-27, with positive outlook on profitability and potential import substitution.
→Overall, growth is anticipated to return once global trade volatility settles and normal business cycles resume.
→Long-term, the company aims for gradual upward volume trends, with capacity to scale production up to ~2 lakh tons (production) depending on market demand.

📈 Profitability & Margins

→The first half of FY'26 has been subdued with marginal volume growth and flat topline due to demand pressures and geopolitical factors.
→Volume growth expected to be lower than the usual 10-15% for FY'26.
→Margins have been protected despite pricing pressures.
→Demand is currently subdued across agrochemicals, pharma, and other industries but may improve if global trade volatility settles.
→Capacity expansions, such as the new plant with a CAPEX of ~Rs. 120 crores, are expected to come online by early FY'27, potentially driving volume growth.
→Acetonitrile capacity utilization may require expansion if demand grows; exports continue worldwide.
→Overall growth depends on normalization of global trade and market demand; positive trend expected post volatility.
→Management optimistic about returning to normal growth levels similar to or above pre-COVID volumes and profitability over time.

See what Alkyl Amines Chemicals Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→Alkyl Amines Chemicals has ongoing capital expenditure at Kurkumbh for a new product, expected to be mechanically completed between February-March 2026, with commercialization in Q1 of FY 2026-27.
→The CAPEX for this new product is approximately Rs. 120 crores.
→This product targets dyes, pigments, electronics sectors and serves as an import substitute, with no current domestic competitor.
→Asset turnover expected for this new product is about 1.5 times.
→For acetonitrile (ACN), potential future capacity expansion depends on market growth and capacity utilization; no immediate CAPEX decisions will be made until utilization justifies it.
→Typical timeline for setting up a continuous process plant is about 2 years, including around 1 year for environment clearances.
→Last plant setup was in the range of Rs. 150-160 crores, possibly higher now.

💰 Fundraising & Capital Structure

→There is no specific mention of any current or future fundraising through debt or equity in the provided transcript.
→The company discussed capital expenditure (CAPEX) plans, e.g., a new plant costing around ₹120 crore with commissioning expected in early FY 2026-27, but did not specify the mode of funding.
→Investment decisions, especially for expansions like acetonitrile capacity, will be made based on market demand and capacity utilization, indicating caution towards large investments.
→No direct reference was made to raising funds via debt or equity during the call.

See what Alkyl Amines Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

The transcript from the Alkyl Amines Chemicals Limited earnings call does not provide specific information about the current or expected order book or pending orders. Key points related to business and operations are: - Demand is currently subdued across AgroChem, pharma, and other industries due to geopolitical and trade uncertainties. - Volume growth in the first half of FY'26 has been marginally up but below earlier expectations, indicating subdued market demand. - New product launches and capacity expansions are underway, such as a new plant costing around Rs. 120 crores expected to be operational by early FY'27. - Capacity utilization and expansion decisions, especially for acetonitrile, depend on market demand growth. - Management expects demand and trade situations to stabilize, leading to normal business growth levels in the future. No direct commentary on pending orders or a defined order book is mentioned.

Key Metrics

How does Alkyl Amines Chemicals Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Alkyl Amines Chemicals Ltd

See full Chemicals & Petrochemicals sector rankings

What Alkyl Amines Chemicals Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

IPHL (Q2 FY26)
H1 FY 25-26 revenue increased by ~15% to ₹451 crores versus ₹385 crores in H1 FY 24-25. Key concall takeaways from Indian Phosphate's Q2 FY26 earnings call…
SUDARSCHEM (Q2 FY26)
The company completed a significant capex investment of roughly INR 700 crores about 3-4 years ago. Key concall takeaways from Sudarshan Chemical Industries…
GNFC (Q2 FY26)
Capex pipeline worth INR 2,800 crores includes expansions in AN melt, weak nitric acid, power and steam plant conversion, and ammonia loop expansion. Key…
PIDILITIND (Q2 FY26)
Growth in the Consumer and Bazaar segment sustained at 10%, driven by core and pioneering categories like Roff and electronic adhesives (Page 7). Key concall…

Compare:vs Solar Industries India Ltd vs PIDILITIND vs SRF

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Alkyl Amines Chemicals Ltd Q2 FY26 results?

What is Alkyl Amines Chemicals Ltd share price analysis?

Alkyl Amines Chemicals Ltd currently shows a neutral. The stock trades at a P/E of 44.1 with a market cap of ₹9,921 Cr. Investors should review the full earnings analysis for detailed insights.

Is Alkyl Amines Chemicals Ltd planning capital expenditure?

Alkyl Amines Chemicals has ongoing capital expenditure at Kurkumbh for a new product, expected to be mechanically completed between February-March 2026, with commercialization in Q1 of FY 2026-27. - The CAPEX for this new product is approximately Rs.

Keep Alkyl Amines Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.